Cargando…
Assay establishment and validation of a high-throughput organoid-based drug screening platform
BACKGROUND: Organoids are three-dimensional structures that closely recapitulate tissue architecture and cellular composition, thereby holding great promise for organoid-based drug screening. Although growing in three-dimensional provides the possibility for organoids to recapitulate main features o...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137096/ https://www.ncbi.nlm.nih.gov/pubmed/35619149 http://dx.doi.org/10.1186/s13287-022-02902-3 |
_version_ | 1784714306013626368 |
---|---|
author | Li, Xiaomeng Fu, Guoxiang Zhang, Long Guan, Ruoyu Tang, Peiyuan Zhang, Jialing Rao, Xinxin Chen, Shengzhi Xu, Xiaoya Zhou, Yi Deng, Yun Lv, Tao He, Xingfeng Mo, Shaobo Mu, Peiyuan Gao, Jianjun Hua, Guoqiang |
author_facet | Li, Xiaomeng Fu, Guoxiang Zhang, Long Guan, Ruoyu Tang, Peiyuan Zhang, Jialing Rao, Xinxin Chen, Shengzhi Xu, Xiaoya Zhou, Yi Deng, Yun Lv, Tao He, Xingfeng Mo, Shaobo Mu, Peiyuan Gao, Jianjun Hua, Guoqiang |
author_sort | Li, Xiaomeng |
collection | PubMed |
description | BACKGROUND: Organoids are three-dimensional structures that closely recapitulate tissue architecture and cellular composition, thereby holding great promise for organoid-based drug screening. Although growing in three-dimensional provides the possibility for organoids to recapitulate main features of corresponding tissues, it makes it incommodious for imaging organoids in two-dimensional and identifying surviving organoids from surrounding dead cells after organoids being treated by irradiation or chemotherapy. Therefore, significant work remains to establish high-quality controls to standardize organoid analyses and make organoid models more reproducible. METHODS: In this study, the Z-stack imaging technique was used for the imaging of three-dimensional organoids to gather all the organoids’ maximum cross sections in one imaging. The combination of live cell staining fluorescent dye Calcein-AM and ImageJ assessment was used to analyze the survival of organoids treated by irradiation or chemotherapy. RESULTS: We have established a novel quantitative high-throughput imaging assay that harnesses the scalability of organoid cultures. Using this assay, we can capture organoid growth over time, measure multiple whole-well organoid readouts, and show the different responses to drug treatments. CONCLUSIONS: In summary, combining the Z-stack imaging technique and fluorescent labeling methods, we established an assay for the imaging and analysis of three-dimensional organoids. Our data demonstrated the feasibility of using organoid-based platforms for high-throughput drug screening assays. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-02902-3. |
format | Online Article Text |
id | pubmed-9137096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91370962022-05-28 Assay establishment and validation of a high-throughput organoid-based drug screening platform Li, Xiaomeng Fu, Guoxiang Zhang, Long Guan, Ruoyu Tang, Peiyuan Zhang, Jialing Rao, Xinxin Chen, Shengzhi Xu, Xiaoya Zhou, Yi Deng, Yun Lv, Tao He, Xingfeng Mo, Shaobo Mu, Peiyuan Gao, Jianjun Hua, Guoqiang Stem Cell Res Ther Research BACKGROUND: Organoids are three-dimensional structures that closely recapitulate tissue architecture and cellular composition, thereby holding great promise for organoid-based drug screening. Although growing in three-dimensional provides the possibility for organoids to recapitulate main features of corresponding tissues, it makes it incommodious for imaging organoids in two-dimensional and identifying surviving organoids from surrounding dead cells after organoids being treated by irradiation or chemotherapy. Therefore, significant work remains to establish high-quality controls to standardize organoid analyses and make organoid models more reproducible. METHODS: In this study, the Z-stack imaging technique was used for the imaging of three-dimensional organoids to gather all the organoids’ maximum cross sections in one imaging. The combination of live cell staining fluorescent dye Calcein-AM and ImageJ assessment was used to analyze the survival of organoids treated by irradiation or chemotherapy. RESULTS: We have established a novel quantitative high-throughput imaging assay that harnesses the scalability of organoid cultures. Using this assay, we can capture organoid growth over time, measure multiple whole-well organoid readouts, and show the different responses to drug treatments. CONCLUSIONS: In summary, combining the Z-stack imaging technique and fluorescent labeling methods, we established an assay for the imaging and analysis of three-dimensional organoids. Our data demonstrated the feasibility of using organoid-based platforms for high-throughput drug screening assays. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-02902-3. BioMed Central 2022-05-26 /pmc/articles/PMC9137096/ /pubmed/35619149 http://dx.doi.org/10.1186/s13287-022-02902-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Xiaomeng Fu, Guoxiang Zhang, Long Guan, Ruoyu Tang, Peiyuan Zhang, Jialing Rao, Xinxin Chen, Shengzhi Xu, Xiaoya Zhou, Yi Deng, Yun Lv, Tao He, Xingfeng Mo, Shaobo Mu, Peiyuan Gao, Jianjun Hua, Guoqiang Assay establishment and validation of a high-throughput organoid-based drug screening platform |
title | Assay establishment and validation of a high-throughput organoid-based drug screening platform |
title_full | Assay establishment and validation of a high-throughput organoid-based drug screening platform |
title_fullStr | Assay establishment and validation of a high-throughput organoid-based drug screening platform |
title_full_unstemmed | Assay establishment and validation of a high-throughput organoid-based drug screening platform |
title_short | Assay establishment and validation of a high-throughput organoid-based drug screening platform |
title_sort | assay establishment and validation of a high-throughput organoid-based drug screening platform |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137096/ https://www.ncbi.nlm.nih.gov/pubmed/35619149 http://dx.doi.org/10.1186/s13287-022-02902-3 |
work_keys_str_mv | AT lixiaomeng assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT fuguoxiang assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT zhanglong assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT guanruoyu assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT tangpeiyuan assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT zhangjialing assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT raoxinxin assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT chenshengzhi assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT xuxiaoya assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT zhouyi assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT dengyun assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT lvtao assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT hexingfeng assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT moshaobo assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT mupeiyuan assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT gaojianjun assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform AT huaguoqiang assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform |